First gene therapy for prevalent patholog... - Cure Parkinson's
First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
3 Replies
•
"EG110A to start Phase 1b/2a clinical study in Neurogenic Detrusor Overactivity (NDO) patients
NDO is a severe bladder condition affecting millions of patients living with Spinal Cord Injury, Multiple Sclerosis, Parkinson’s disease and other neurological disorders
Other severe pathologies of the bladder to be investigated following this study
Preclinical data show EG110A’s potential for long-lasting efficacy on urinary continence and to address shortcomings of existing therapies"
not on clinical trials.gov yet
I went on there to try to find the locations for the trials
This is not a trial my husband would participate in however this information could be helpful
